Preparation and characterization of co-processed starch/MCC/chitin hydrophilic polymers onto magnesium silicate

It was aimed to investigate the compressibility, compactibility, powder flow and tablet disintegration of a new excipient comprising magnesium (Mg) silicate co-processed (5%–85% w/w) onto chitin, microcrystalline cellulose (MCC) and starch as the hydrophilic polymers of interest. Initially, the mechanism of tablet disintegration was studied by measuring water infiltration rate, moisture sorption, swelling capacity and hydration ability. Moreover, the powders compression behavior was carried out by applying Kawakita model of compression analysis in addition to porosity and radial tensile strength measurements. In vitro drug release of compacts made of 400?mg ibuprofen and 300?mg of the hydrophilic polymers containing 30% w/w Mg silicate co-precipitate was investigated in phosphate buffer (pH 7.8). This work demonstrated that the incorporation of Mg silicate to the hydrophilic polymers lead to the improvement of powder flowability, compactibility, stability (with regard to storage conditions), compacts crushing strength, and disintegration time in addition to faster drug release. The overall findings are practically advantageous in the context of finding a low cost and multifunctional co-processed excipient of natural origins.     

隔药饼灸对慢性支气管炎模型大鼠外周血中T细胞亚群的影响

目的:观察隔药饼灸对慢性支气管炎模型大鼠外周血中T细胞亚群含量的影响,探讨隔药饼灸防治慢性支气管炎的可能机制。方法:48只SD大鼠随机分为空白组、模型组、隔药饼灸组、核酪口服液组4组各12只,采用改良烟熏法复制慢性支气管炎大鼠模型,流式细胞术检测血清中T细胞亚群含量变化。结果:与空白组比较,模型组大鼠外周血中CD^4+、CD^8+、CD^ 4+/CD^8+明显降低;与模型组比较,隔药饼灸组、核酪口服液组CD^4+、CD^8+及CD^4+/CD^8+升高;与核酪口服液组比较,隔药饼灸组CD^4+、CD^8+、CD^4+/CD^8+升高更明显。结论:隔药饼灸可能通过上调外周血中CD^4+、CD^8+T细胞亚群含量,提高CD^4+/CD^8+,起到对慢性支气管炎的防治作用。     

噻托溴铵粉吸入剂治疗148例支气管扩张症的效果评定

目的观察噻托溴铵粉吸入剂应用于临床治疗支气管扩张症的效果。方法选取我院治疗的148例支气管扩张症患者,随机分为观察组和对比组,对比组给予常规的支气管扩张症治疗;观察组在进行常规治疗的同时给予噻托溴铵粉吸入剂进行治疗。结果治疗后观察组和对比组的BODE指数和临床症状均有改善,但观察组优于对比组,P0.05,差异具有统计学意义。结论使用噻托溴铵粉吸入剂治疗支气管扩张症疗效显著。     

青黛粉联合抗生素治疗糖尿病皮肤感染疗效观察

目的:观察青黛粉联合抗生素治疗糖尿病皮肤感染的临床疗效。方法:选取2009年1月~2012年1月期间在本院皮肤科住院治疗的80例糖尿病皮肤感染患者为研究对象,采用分组对照法,观察组40例采用青黛粉+红霉素敷料换药,对照组40例单纯采用红霉素敷料,回顾性分析两种用药方法的效果。结果:治疗7d后观察组8例(占20%)患者感染创面为重度,对照组为2例(占5%),组间比较μ=3.221,7.609,P<0.05,观察组51个创面,总有效率为90.56%,对照组53个创面,总有效率为84.51%,μ=1.879,P<0.05,提示青黛粉联合抗生素治疗糖尿病皮肤感染疗效显著好于未加青黛粉的对照组,差异显著,有统计学意义。结论:加用青黛粉的观察组疗效显著好于单纯使用抗生素的对照组,有助于缩短疗程,加快皮肤感染组织的修复,促进早期愈合,疗效确切,值得临床推广应用。     

生脉散合血府逐瘀汤治疗冠心病气阴两虚血瘀证的临床疗效观察

目的 观察应用生脉散联合血府逐瘀汤治疗冠心病气阴两虚血瘀证的效果。方法 选取2016年1月—2017年12月我院心内科收治的冠心病患者100例，根据入院顺序平均分为常规组和研究组，常规组患者实施常规西医治疗，研究组患者加用生脉散联合血府逐瘀汤治疗，观察两组的治疗效果及相关指标。结果 研究组患者的治疗有效率为90%，明显高于常规组的74%(P＜0.05)；两组患者治疗后的中医症状积分、心绞痛发作次数和6 min步行试验均明显优于治疗前(P＜0.05)，且研究组患者治疗后3个指标更优(P＜0.05)。结论 生脉散联合血府逐瘀汤可以提高临床冠心病气阴两虚血瘀证的治疗效果，缓解患者症状和心绞痛发作，有助于6 min步行试验改善。     

柴胡疏肝散联合四君子汤治疗慢性萎缩性胃炎的临床效果

目的研究柴胡疏肝散联合四君子汤治疗慢性萎缩性胃炎(CAG)的临床效果。方法将2014年10月至2019年10月于我院治疗的96例CAG患者随机分为对照组和研究组,各48例。对照组给予柴胡疏肝散治疗,研究组在对照组基础上加用四君子汤治疗。比较两组患者的临床疗效、Hp根除率、胃镜病理检查评分、症状积分及生活质量。结果研究组治疗总有效率及Hp根除率明显高于对照组(P<0.05)。治疗后,两组胃镜病理检查评分、主要症状积分和次要症状积分均降低,GQOL-74各项评分均提高,且研究组显著优于对照组(P<0.05)。结论柴胡疏肝散联合四君子汤治疗CAG可显著改善患者胃部病理状态和临床症状,提高临床疗效、Hp根除率和患者生活质量,值得临床推广应用。     

毫火针联合中药药膜外敷治疗轻中度痤疮疗效观察

目的:探讨毫火针联合中药药膜外敷治疗轻中度痤疮患者的临床效果和安全性。方法:将100例门诊确诊为轻中度痤疮的患者随机分成两组。治疗组:50例,使用毫火针配合中药药膜外敷治疗(每周2次,8周为1个疗程);对照组:50例,仅采用毫火针治疗(每周2次,8周为1个疗程),治疗1个疗程后观察两组的治疗效果及安全性。结果:治疗组:治愈6例,显效19例,有效22例,总有效率94.0%;对照组:治愈3例,显效12例,有效25例,总有效率80.0%,两组疗效比较差异有统计学意义(P<0.05)。治疗后,治疗组患者DLQI积分为2.52±0.81,显著低于对照组,差异具有统计学意义(P<0.05);治疗后,治疗组患者的DLQI积分下降幅度显著高于对照组,差异具有统计学意义(P<0.05)。治疗期间,治疗组发生不良反应1例,发生率为2%;对照组未发现明显不良反应,差异无统计学意义(P>0.05)。结论:毫火针联合中药药膜外敷治疗轻中度痤疮安全、有效。     

皮肤保护粉和防漏膏在改进肠造口护理中的应用

目的探讨皮肤保护粉和防漏膏在结肠造口术中护理的重要作用。方法从2012年1—11月,肠造口病人资料24例,采用皮肤保护粉和防漏膏护理方法。结果无一例出现造口周围皮肤湿疹,糜烂,大大缩短了住院时间。结论在肠造口护理中正确使用皮肤保护粉和防漏膏,可以减少肠造口引起的一些并发症,以减轻患者痛苦,提高肠造口患者的生活质量。     

Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery

Co-administration of an inhaled corticosteroid and long acting beta agonist for chronic obstructive pulmonary disease has reduced mortality compared to either drug alone. This combination reduces exacerbations, hospitalization, emergency department visits and health care costs. A novel fixed-dose combination of the long acting beta-2 agonist salmeterol xinafoate (SX) and the corticosteroid mometasone furoate (MF) were prepared in a composite particle formulation as brittle matrix powder (BMP) and investigated for suitability as an inhaled combination product. In this study, BMP fixed dose combinations of SX and MF with or without stabilizing excipients (lactose, mannitol, glycine and trehalose) were prepared and characterized with respect to their thermal properties, morphology, aerodynamic performance and physical stability. BMP combination formulations of SX and MF exhibited improved aerodynamic properties when delivered by dry powder inhalation as compared to the micronized blends of the same substances. Aerodynamic evaluation was carried out by next generation pharmaceutical impactor (NGI) with a marketed DPI device. Results demonstrated that co-deposition occurred when SX and MF were formulated together as composite particles in a BMP, while physical blends resulted in inconsistent deposition and dose uniformity. As a result of the bottom-up particle engineering approach, combination BMP formulations allow for dual API composite formulations to be dispersed as aerosolized particles. Aerosolized BMP combination formulations resulted in delivered dose uniformity and co-deposition of each API. Further, an excipient-free formulation, BMP SXMF, delivered approximately 50% of the loaded dose in the respirable range and demonstrated stability at ambient conditions for 6 months. Single dose 24-h pharmacokinetic studies in rats demonstrated that lung tissue deposition and blood circulation (AUC_0–24h) of two APIs were higher for the BMP combination group exhibiting a significantly higher lung concentration of drugs than for the crystalline physical blend. While high system drug levels are generally undesirable in lung targeted therapies, high blood levels in this rodent study could be indicative of increased pulmonary tissue exposure using BMP formulations.     

蒙脱石散联合双歧杆菌乳杆菌三联活菌片治疗小儿急性腹泻的临床分析

目的探讨蒙脱石散联合双歧杆菌乳杆菌三联活菌片治疗小儿急性腹泻的临床疗效。方法选取我院自2013年2月~2014年2月接收的80例小儿急性腹泻患儿,随机分为观察组和对照组,每组40例,对照组行单纯蒙脱石散治疗,观察组则行蒙脱石散联合双歧杆菌乳杆菌三联活菌片治疗,比较两组患儿的临床疗效。结果 两组患儿治疗总有效率、退热时间、呕吐消失时间、腹痛消失时间、大便正常时间等比较均有显著性差异(P0.05)。结论 给予急性腹泻患儿蒙脱石散联合双歧杆菌乳杆菌三联活菌片治疗可有效的提高治疗效果,改善患儿临床症状。